Best Vitelliform Macular Dystrophy

Stephen H Tsang; Tarun Sharma

doi:10.1007/978-3-319-95046-4_16

Best Vitelliform Macular Dystrophy

Adv Exp Med Biol. 2018:1085:79-90. doi: 10.1007/978-3-319-95046-4_16.

Authors

Stephen H Tsang^{1

2}, Tarun Sharma³

Affiliations

¹ Jonas Children's Vision Care, Bernard & Shirlee Brown Glaucoma Laboratory, Columbia Stem Cell Initiative-Departments of Ophthalmology, Biomedical Engineering, Pathology & Cell Biology, Institute of Human Nutrition, Vagelos College of Physicians and Surgeons, Columbia University, New York, NY, USA.
² Department of Ophthalmology, Columbia University, Edward S. Harkness Eye Institute, NewYork-Presbyterian Hospital, New York, NY, USA.
³ Department of Ophthalmology, Columbia University, Edward S. Harkness Eye Institute, NewYork-Presbyterian Hospital, New York, NY, USA. ts3118@cumc.columbia.edu.

PMID: 30578489
DOI: 10.1007/978-3-319-95046-4_16

Abstract

Best vitelliform macular dystrophy (VMD or BVMD) is one of the most common macular dystrophies, affecting 1 in 10,000 individuals. The clinical presentation varies, depending on the stage of the disease at which the patient presents, usually one of these five stages: Previtelliform Vitelliform (Figs. 16.1, 16.2, 16.3 and 16.4) Pseudohypopyon Vitelliruptive (Fig. 16.5) Atrophic.

Keywords: Autosomal dominant; Best disease.

Publication types

Review

MeSH terms

Humans
Vitelliform Macular Dystrophy / physiopathology*